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Kras-driven non–small-cell lung cancers (NSC LCs) are a leading cause of death with limited therapeutic options. Many NSC LCs 
exhibit high levels of Ezh2, the enzymatic subunit of polycomb repressive complex 2 (PRC2). We tested Ezh2 inhibitors as 
single agents or before chemotherapy in mice with orthotopic Kras-driven NSC LC grafts, which homogeneously express 
Ezh2. These tumors display sensitivity to EZH2 inhibition by GSK126 but also amplify an inflammatory program involving 
signaling through NF-κB and genes residing in PRC2-regulated chromatin. During this process, tumor cells overcome GSK126 
antiproliferative effects. We identified oncogenes that may mediate progression through an in vivo RNAi screen aimed at 
targets of PRC2/NF-κB. An in vitro compound screening linked GSK126-driven inflammation and therapeutic vulnerability in 
human cells to regulation of RNA synthesis and proteostasis. Interestingly, GSK126-treated NSC LCs in vivo also showed an 
enhanced response to a combination of nimesulide and bortezomib. Thus, Ezh2 inhibition may restrict cell proliferation and 
promote defined adaptive responses. Targeting these responses potentially improves outcomes in Kras-driven NSC LCs.
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Introduction
Ras signaling is a major oncogenic driver of human cancers, but 
there are currently no therapies that effectively target tumors 
with driver mutations in Ras genes (Vivanco, 2014). Non–small-
cell lung cancer (NSC LC) is the most prevalent form of cancer in 
the western world, and ∼35% of all patients exhibit mutations in 
Kras, a key component of the Ras pathway (Cancer Genome Atlas 
Research Network, 2014; Chen et al., 2014).
Ezh2 is the enzymatic component of polycomb repressive com-
plex 2 (PRC2). This complex is responsible for the transcriptional 
repression of many genes and contributes to the maintenance of 
cell identities in multiple tissues. To exert these functions, the 
PRC2 holoenzyme, which also includes nonenzymatic compo-
nents such as Eed and Suz12, catalyzes trimethylation of lysine 
27 on histone H3; this modification in the promoter regions of 
genes is often a crucial step in their silencing (Margueron and 
Reinberg, 2011). NSC LCs and many other tumors exhibit Ezh2 
overexpression, which is considered oncogenic and is used as a 
prognostic factor for outcomes in several human cancers. EZH2 
has attracted significant interest as a potential target for drugs, 
because its inhibition would presumably lead to a reactivation 
of silenced tumor suppressor genes. In NSC LC, it is proposed 
that when Ezh2 is overexpressed, cells fail to transcribe tumor 
suppressor genes and microRNAs that would otherwise restrict 
tumor growth (Friedman et al., 2009).
A global deletion of Ezh2 is embryonically lethal (O’Carroll 
et al., 2001), but Ezh2 can be depleted in adult animals without 
causing significant problems: 12 wk of continuous Ezh2 systemic 
inhibition in adult animals carrying a doxycycline (dox)-induc-
ible shRNA significantly depletes Ezh2 mRNA and protein with-
out causing overt tissue phenotypes (Michalak et al., 2013). The 
S-adenosylhomocysteine hydrolase inhibitor DZnep proved to ef-
ficiently target the enzyme and to impair tumor growth in a sub-
set of NSC LC genotypes with epidermal growth factor receptor 
(EGFR) or BRG1 mutations when combined with the topoisomer-
ase II inhibitor etoposide (Fillmore et al., 2015). However, DZnep 
is unlikely to gain momentum as an Ezh2 inhibitor in clinical tri-
als due to significant off-target effects and toxicity (Miranda et 
al., 2009). Nevertheless, more specific S-adenosylhomocysteine–
competitive Ezh2 inhibitors have recently completed preclinical 
testing successfully (Sneeringer et al., 2010; McCabe et al., 2012).
Multiple synthetic lethal screens conducted to find Kras 
mutant associated vulnerabilities converged on indicating an 
important requirement for proteasome activity in Ras mutant 
solid tumors (Barbie et al., 2009; Luo et al., 2009; Kumar et al., 
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2012). The proteasome inhibitor bortezomib (BTZ; clinical name 
Velcade) is approved for use to treat patients with multiple my-
eloma. BTZ is believed to act through an inhibition of the pro-in-
flammatory and proto-oncogenic transcription factor NF-κB. 
Proteasomal degradation of IkBα, an endogenous inhibitor of the 
pathway that directly interacts with NF-κB to sequester it in the 
cytoplasm (Demchenko and Kuehl, 2010), is a critical step in the 
constitutive self-inhibition of the NF-κB found in healthy cells 
(Arkan and Greten, 2011; Hinz et al., 2012). It has been shown that 
BTZ treatment of multiple myeloma prevents the degradation of 
IkBα. Currently, BTZ is being tested in a phase 2 clinical trial in 
patients with KrasG12D mutant NSC LC (NCT01833143). However, 
BTZ alone or in combination with pemetrexed in previous stud-
ies did not significantly extend the overall survival in NSC LC pa-
tients (Scagliotti et al., 2010), indicating that specific treatment 
combinations may be required.
NF-κB is a critical promoter of tumor progression, including 
in NSC LC. In a Kras-driven genetically engineered mouse model 
reflecting NSC LC biology and response to therapy (Jackson et al., 
2001; Johnson et al., 2001; Singh et al., 2010), deletion of NF-κB 
severely impairs tumor growth (Meylan et al., 2009). Impor-
tantly, the proapoptotic response in tumor cells upon pharma-
cological inhibition of NF-κB appeared to be context dependent 
in Kras-driven NSC LC models (Meylan et al., 2009; Xue et al., 
2011), indicating that additional pathways contribute to modu-
lating NF-κB dependences.
Recently, we showed that PRC2 inhibition by Eed deletion pro-
motes the acquisition of an inflammatory phenotype in a con-
text-dependent manner (Serresi et al., 2016). The link between 
PRC2 inhibition, inflammation, and Kras-driven tumorigenesis 
is also found in the pancreas. Loss of EZH2 results in persistent 
inflammation during pancreatic homeostasis and facilitates 
KrasG12D-driven tumorigenesis. Under these experimental con-
ditions, regular dosing with the anti-inflammatory Cox-2 inhib-
itor nimesulide (NM) preserves tissue homeostasis and delays 
neoplastic initiation (Mallen-St Clair et al., 2012).
In summary, there is ample evidence supporting the idea that 
a combination of Ezh2 inhibitors and anti-inflammatory agents 
might provide an effective treatment for a subset of KrasG12D-
driven NSC LCs. Here, we investigate how orthotopic grafts of 
KrasG12D-driven NSC LC cells respond to a clinically relevant 
Ezh2 inhibitor and investigate the adaptive response mecha-
nisms with a view toward selectively exploiting chemotherapy 
to target acquired vulnerabilities in a sequential or “neoadju-
vant-like” dosing scheme.
Results
Ezh2 is important for proliferation of Kras-driven NSC LC cells
To investigate the role of Ezh2 in KrasG12D/+ NSC LC cells, 
we established primary cultures from mouse KrasG12D/+ and 
KrasG12D/+;Trp53−/− lung adenocarcinoma tumors. Applying the 
Ezh2-specific inhibitor GSK343 resulted in a down-regulation 
of H3K27me3 and led to reduced cell proliferation and colony 
formation as compared with cultures treated with an inactive 
control compound. This occurred in both genotypes (Fig.  1, 
A–C). Similar results were obtained with stable dox-inducible 
Ezh2 depletion or with transient siRNAs, without affecting the 
level of expression of other polycomb protein members (Fig. 1 D). 
To totally deplete activity for Ezh2 in NSC LC cells, we combined 
simultaneous dox and GSK343 treatment, and this resulted in 
the synergistic inhibition of cell growth (Fig. 1 E). We attributed 
this to a clearly measurable arrest of the cell cycle in the G0/G1 
phase (Fig. 1 F).
To test whether Ezh2 inhibition affected tumor cell prolif-
eration in vivo, we performed orthotopic transplantation ex-
periments. We intratracheally injected the most aggressive 
KrasG12D/+;Trp53−/− cells expressing a dox-inducible short hairpin 
Figure 1. PRC2 regulates in vitro Kras-driven NSC LC cell proliferation and H3K27me3 in a p53-independent manner. (A) KrasG12D/+ and KrasG12D/+;Trp53−/− 
primary cell lines were generated from mouse NSC LC (two per genotype, #1-#2), and enzymatic EZH2 inhibition was performed with the specific GSK343 
compound (100 nM). Immunoblot was performed after 120 h. The inactive GSK669 compound served as a control. (B) Cell numbers relative to the cells in A. 
(C) Representative images of colony-formation assays using 500 cells for the indicated genotypes and treatments. (D) KrasG12D/+;Trp53−/− cells are transduced 
with dox-inducible shRNAs, treated with dox for 72 h, and used for immunoblot (top) and RT-qPCR (bottom) with the indicated antibodies and primers, respec-
tively. (E) Combined dox and GSK343/GSK669 treatment followed by immunoblot (top). The colony-formation assay for the indicated genotypes is performed 
under the same experimental conditions as in A and B (lower panel). (F). Cells were infected with a dox-inducible EZH2 shRNA and treated (or not) with dox 
and GSK343 inhibitor. After 3 d, cells were treated 45 min with BrdU (10 μM), and FACS analysis was performed. One representative cell cycle profile for the 
indicated cell line is shown. Error bars represent SD. P values were calculated using Student’s t test. *, P ≤ 0.05; **, P ≤ 0.01; ***, P ≤ 0.001. Data are based on 
three independent experiments.
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to knock down Ezh2 (Ezh2i) or GFP (GFPi) as control. The NSC LC 
cells were also transduced with luciferase to permit longitudinal 
assessments of grafting success and tumor progression. The tu-
mors that developed in these orthotopic models homogeneously 
expressed Ezh2 at high levels (Fig. 2 A). We continuously admin-
istered dox through the drinking water, leading to the depletion 
of Ezh2, followed by a significant impairment of the formation of 
adenomas compared with the GFPi controls (Fig. 2 B). At the se-
lected time point, the lung lesions of mice that received the Ezh2i 
cells were significantly smaller; they generally scored as mild 
hyperplasia and rarely progressed to severe hyperplasia or ade-
noma in contrast to the GFPi controls (Fig. 2 C; data not shown).
Next, we turned to tail vein grafting and used noninvasive bio-
luminescence. In contrast to the intratracheal procedure, via tail 
vein injection, efficient lung colonization occurred before genetic 
depletion, and animals bearing Ezh2-depleted tumors developed 
lung cancer, possibly because of reduced impact of grafting 
stress. Yet, a moderate and significant increase in the lifespan 
of the Ezh2i group was observed compared with GFPi control 
mice (Fig. 2 D). Similar results were obtained when depleting 
Eed, another component of the PRC2 complex (see below). Most 
importantly, a pharmacological approach based on daily dosing 
of GSK126, a clinically relevant Ezh2 inhibitor, also promoted a 
moderate and significant tumor growth inhibition and exten-
sion in survival (Fig. 2 E). Luciferase imaging was performed at 
day 2 (when lung colonization is complete) and again 20 d after 
treatment (when control animals display shortness of breath). 
The comparison indicated that the growth of tumors is reduced 
in GSK126-treated mice (data not shown). In a time-course ex-
periment, histological analysis revealed that lung lesions ex-
posed to GSK126 for 10 d are on average significantly smaller and 
display a pale cytoplasm compared with vehicle-treated ones 
(Fig. 2, F and G). To confirm that the in vivo effects of GSK126 
on NSC LC progression are on target, we performed immunohis-
tochemistry (IHC) to detect histone H3K27 tri-methylation, the 
enzymatic product of Ezh2, and found significant depletion of 
this histone mark in the treated tumors compared with controls 
(Fig. 2, H and I).
These results suggest that the function of PRC2 is important 
for the proliferation of KrasG12D-driven NSC LC cells. In addition, 
orthotopic transplantation of these cells represents a practical 
in vivo model for studying treatment response and develop-
ment of resistance to therapeutic intervention in lung lesions 
expressing Ezh2.
Ezh2 inhibition promotes the transcriptional amplification of 
an inflammatory program involving NF-κB and dampens EGFR/
ERBB2 signaling
To investigate the mechanisms behind the cellular responses to 
PRC2 inhibition in vivo, we performed genome-wide expression 
profiling of freshly isolated cells from tumors derived from intra-
venous transplantations. The different methods to inhibit Ezh2 
(treatment with GSK126 or the administration of dox) allowed us 
to distinguish between effects that were the direct result of EZH2 
inhibition versus off-target effects due to the specific treatment.
As the effects of Ezh2 inhibition in the tumors could be de-
pendent on genes directly regulated by PRC2 and on secondary 
effects, we purified tumor cells at two time points to capture both 
types of data. The first was at 12 d after the introduction of tumor 
cells, an asymptomatic stage in which Ezh2 depletion is tumor 
suppressive (Fig. 2, F and G) and representing half of the median 
survival time in control animals (hereafter referred to as OS50). 
The second time point was the individual onset of severe short-
ness of breath (up to 30 d; hereafter referred to as humane end-
point [HuE]). To yield an enrichment of tumor cells, we isolated 
GFP-expressing tumor cells by FACS (Fig. 3 A).
To characterize the transcriptional response, we compared 
tumor cells derived from vehicle/GSK126 with dox-treated orthot-
opic models and identified differentially regulated genes (DRGs). A 
normalization of the RNA sequencing (RNA-seq) reads over vehi-
cle-treated controls revealed a striking number of DRGs in tumor 
cells treated with Ezh2 inhibitors (Fig. 3 B). To identify differences 
reflecting changes in signaling pathways, we used a method called 
PRO GENy. This method analyzes gene expression data and ranks 
patterns observed in activated pathways by consulting a curated 
database that includes the effects of human cancer driver muta-
tions and drug perturbations (Schubert et al., 2018). The pathways 
most highly activated by GSK126, according to this analysis, were 
NF-κB and its upstream regulator, TNF-α, followed by the JAK/
STAT pathway, which is activated, among others, by IL-6 (Fig. 3 C).
Next, we used Ingenuity Pathway Analysis (IPA) to capture the 
information of both activated and inactivated pathways. In the 
latter category, we found a connection to the extended survival of 
GSK126-treated animals, because several of the genes that were 
down-regulated by the treatment played a role in tumor cell pro-
liferation, such as those in the EGFR/ERBB2 signaling pathway 
(Fig. 3 D). We independently validated this finding by probing 
GSK126-treated and controls for ERK1/2 phosphorylation, which 
acts as a molecular beacon downstream in this signaling cas-
cade (Fig. 3 E).
To identify genes that were potentially being directly re-
pressed by PRC2, we analyzed all the genes that underwent 
up-regulation compared with controls. The results of IPA con-
firmed and extended the outcome from PRO GENy; the majority 
of these up-regulated genes belonged to inflammation-related 
pathways (113/212 [53%]; Fig. 3 F). The amplified inflammatory 
signature includes TNF, LPS, IFN-γ, and IL-6, which reinforces 
the prediction that the NF-κB transcriptional network is being 
activated (Fig. 3 F). The gene list includes potential oncogenes 
such as CXCR4, VAV1, and CEBP-β, alongside critical targets 
such as CD47 and SIR PA that modulate immunosurveillance 
and are targets for immunotherapy (Fig. 3 G). IHC in indepen-
dent tumors in which Ezh2 had been down-regulated by dox 
(KrasG12D/+;Trp53−/−;Ezh2i+dox) confirmed that the Ezh2 loss is 
specifically associated with an up-regulation of these proteins in 
vivo (Fig. 3 H). To understand the relevance of these oncogenes 
in the progression of human NSC LC, we queried a large dataset 
from The Cancer Genome Atlas (TCGA; http:// www .cbioportal 
.org). Given that these targets were discovered mainly as PRC2 
target in lung adenocarcinoma and thereby lowly expressed in 
this malignancy, we tested their prognostic significance as onco-
genes in a different subtype of lung cancer. In lung squamous car-
cinoma patients, the elevated expression of CXCR4, VAV1, CEBP, 
and CD47 was correlated with poor patient prognosis (Fig. 3 I).
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As we have recently shown that loss of the PRC2 gatekeeper 
Eed promotes inflammation and epithelial-to-mesenchymal 
transition (EMT) in autochthonous models of Kras-driven 
NSC LC (Serresi et al., 2016), we next wished to understand 
whether pharmacological Ezh2 inhibition phenocopies Eed 
deletion in full. To this end, we compared RNA-seq on in vivo 
GSK126-treated KrasG12D/+;Trp53−/− and controls to those gener-
ated by limited ex vivo propagation of KrasG12D/+;Trp53−/− and 
KrasG12D/+;Trp53−/−;Eed−/− tumor cells. We subjected the RNA-
seq profiles to unbiased principal component analysis (PCA) 
and clustering based on Pearson correlation. These analyses 
confirmed that in GSK126-treated tumors, the transcriptional 
amplification of genes related to acute inflammation seemed 
to be specifically associated with the in vivo enzymatic inhibi-
tion of Ezh2 by GSK126 (Fig. 3 J; data not shown). In contrast, 
genes involved in cellular morphogenesis and EMT remained 
associated only with cells in which Kras tumorigenesis occurred 
in the absence of PRC2 as an outcome of Eed deletion in non-
transformed cells.
Overall, this analysis indicates that in vivo PRC2 inhibition has 
milder consequences than PRC2 deletion during tumor initiation 
in mouse models of Kras-driven NSC LC (Serresi et al., 2016). This 
means that the Ezh2 inhibition triggers the transcriptional am-
plification of a program related to inflammation, but not to EMT.
Transcriptional amplification by Ezh2 inhibition occurs at 
PRC2-regulated chromatin
To gain insights into the mechanistic implications of NSC LC re-
sponse to Ezh2 inhibition in vivo, we next investigated whether 
GSK126-regulated genes involve direct PRC2 targets by interro-
gating a chromatin immunoprecipitation sequencing (ChIP-seq) 
profile of H3K27me3 previously generated in KrasG12D/+;Trp53−/− 
orthotopic lung tumors (Serresi et al., 2016). While prominent 
GSK126-up-regulated genes such as Cxcr4 are indeed deco-
rated with H3K27me3 at CpG islands (CGI), a sizeable fraction 
of DRGs do not belong to the category of classic PRC2 targets 
(Fig. 4, A and B).
To test whether the transcriptional amplification involved 
pre-activated chromatin, we generated ChIP-seq profiling for 
H3K27ac and H2AK5ac in KrasG12D/+;Trp53−/− orthotopic lung 
tumors. Systematically comparing all chromatin profiles with 
input controls using gene set enrichment analysis revealed that 
GSK126–up-regulated genes were located in chromatin signifi-
cantly decorated with either H3K27me3 or H3K27ac, but not 
H2AK5ac (Fig. 4 C).
To investigate whether the inhibition of Ezh2 is sufficient 
to promote the transcriptional activation of the specific set of 
GSK126-regulated genes in tumor cells or additional signaling 
is required, we generated RNA-seq profiles of KrasG12D;Trp53−/− 
NSC LC cells in vitro and compared these profiles to those from the 
in vivo setting. To account for non–cell-autonomous factors, we 
co-cultured tumor cells with the macrophage cell line Raw267.4 
in the presence of short-term Ezh2 inhibition and further mim-
icked proinflammatory stimulation using LPS. Consistent with 
data in Fig. 3 J and the well-known context-dependent function 
attributed to PRC2, comparative analyses indicated that up-reg-
ulation of in vivo GSK126-regulated genes (see Materials and 
methods) is specific for the orthotopic growth setting, whereas 
in vitro Ezh2 inhibition affected the expression of a different set 
of genes (Fig. 4 D).
Since the TNF-α/NF-κB axis was prominently activated in the 
in vivo gene expression profile of GSK126-treated animals, we 
tested whether GSK126 can directly activate the NF-κB pathway 
or reinforce its activation by other pathways. To reach a broad 
conclusion on this matter, we performed this experiment in 
human Kras-driven NSC LC cell lines. Three lines were propa-
gated in the presence of GSK126 or vehicle, and we searched for 
evidence of NF-κB pathway activation by p65 phosphorylation. 
Notably, p65 was phosphorylated in a GSK126-dependent man-
ner in three different cell lines, but only when reseeded at low 
confluence, thereby indicating that Ezh2 inhibition enhances 
NF-κB activation in response to stress (Fig. 4 E). Since a simi-
lar activation of p65 is observed in the three human NSC LC cell 
lines, we next selected A549 cells for subsequent experiments 
and exposed these for 3 h to the NF-κB upstream activator TNF-α 
and measured NF-κB transcriptional activation using a lucifer-
ase reporter (Wilson et al., 2013). This experiment revealed that 
GSK126 treatment enhanced NF-κB activity in response to TNF-α 
stimulation (Fig. 4 F). Importantly, in a continuous stimulation of 
16 h by the NF-κB activators TNF-α and LPS, the transcriptional 
activity of GSK126-treated cells reached a plateau more swiftly 
than control cells (Fig. 4 G).
Thus, our results suggest that Ezh2 inhibition in vivo coop-
erated with inflammatory signaling and facilitates the tran-
scriptional amplification of proinflammatory genes residing in 
PRC2-regulated chromatin.
In vivo Ezh2 inhibition affects the tumor microenvironment
To understand whether Ezh2 inhibition or the observed inflam-
matory activation may result in non–cell-autonomous effects, 
Figure 2. Ezh2 is homogeneously expressed in Kras-driven NSC LC grafts and its inhibition impairs tumor growth in vivo. (A) Ezh2, GFP IHC, and H&E 
stainings of lung adenoma formation after intratracheal transplantation (left) for dox-inducible Ezh2 knockdown (Ezh2i; bottom) compared with controls (GFPi; 
top). (B and C) ImageJ quantification of the tumor burden and frequency distribution of lesions. (D) Overall survival (OS) of mice intravenously transplanted 
with KrasG12D/+;Trp53−/−;Ezh2i (n = 5) or KrasG12D/+;Trp53−/−;GFPi cells (n = 5) and treated with dox drinking water (P < 0.004). (E) Overall survival of mice intra-
venously transplanted with KrasG12D/+;Trp53−/− cells and treated daily with 50 mg/kg GSK126 (n = 10) or vehicle (n = 10, right; P < 0.0003; see also Fig. S1). P 
values are by log-rank (survival). (F) Representative H&E staining of day 12 lung sections from a time-course experiment of mice intravenously transplanted 
with KrasG12D/+;Trp53−/− cells and treated daily with 50 mg/kg GSK126 (n = 4) or vehicle (n = 3). Similar-sized lesions are magnified to show the differential 
cytoplasmic staining. Arrows denote lesions. (G) ImageJ quantification of the tumor burden. a.i., arbitrary intensity. (H) Representative immunofluorescence 
for GSK126 target H3K27me3 and DAPI performed in the same groups as in F. (I) ImageJ quantification of the anti-H3K27me3 intensity. a.u., arbitrary units. 
Five fields were counted per tumor. *, P ≤ 0.05; **, P ≤ 0.01; ***, P ≤ 0.001; ****, P < 0.0001 versus vehicle by unpaired t test. Error bars represent mean ± 
SEM. Scale bars represent 100 µm.
Serresi et al. 
Ezh2 inhibition in Kras-driven NSC LC
Journal of Experimental Medicine
https://doi.org/10.1084/jem.20180801
3120
Serresi et al. 
Ezh2 inhibition in Kras-driven NSC LC
Journal of Experimental Medicine
https://doi.org/10.1084/jem.20180801
3121
we subjected our gene profiling experiment to a bioinformatic 
method by which the immune cell composition within a tissue 
can be inferred (Newman et al., 2015). Despite the fact that our 
RNA-seq profiles were enriched for tumor cells, in silico predic-
tion by CIB ERS ORT (Newman et al., 2015) revealed that orthot-
opic lung cancer grafts present indirect evidence for infiltration 
by activated mast cells (Fig. 5 A). The mast cell signature was 
discovered only within the gene expression profile of freshly 
derived and not ex-vivo–propagated tumor cells. Moreover, the 
orthotopic tumors generated in nude mice had no traces of adap-
tive immune effectors such as CD8 T cells, thereby supporting the 
specificity of this analysis (Fig. 5 A, bottom).
Tumor homeostasis includes infiltration by non–tumor cells 
or events of fusion or phagocytosis between host and donor cells. 
As the mast cell activation signature is shared between GSK126-
treated and naive tumors, the presence of donor- and recipi-
ent-derived RNA molecules offered the opportunity to investigate 
if any of these events could be specifically attributed to GSK126 
(Fig. 5 B). To this end, we applied a method for detecting single-nu-
cleotide polymorphisms (SNPs) in RNA-seq reads independently 
of a reference genome (Lopez-Maestre et al., 2016). Strikingly, 
KisSplice revealed that host-derived BALB/c-specific SNPs were 
selectively enriched in reads from the GSK126-treated cohort, 
with a spike representing a significant contribution from the host 
upon ten days of Ezh2 inhibition, which later fell (P < 0.001; Fig. 5, 
C and D). The specificity of this analysis was confirmed by the fact 
that donor-specific SNPs underwent an opposite regulation (P < 
0.001; Fig. 5, C and D), as well as by the fact that some genes could 
be largely attributed to either genetic background, which suggests 
the host-derived reads may be contributed by a homogeneous cell 
population (Fig. 5 E). In line with CIB ERS ORT, unbiased IPA anal-
ysis of genes uniquely identified by the BALB/c SNPs pointed at a 
leukocyte origin for host-derived reads (Fig. 5 F).
Overall, these data suggest that the in vivo inhibition of Ezh2 
in animals with lung cancer alters the tissue microenvironment.
In vivo RNA interference (RNAi) screening for genes 
antagonistically regulated by PRC2 and NF-κB uncovers 
targets with pro-oncogenic potential
We next investigated whether inflammatory signaling helps by-
passing the growth defect observed in vitro and in vivo in NSC LC 
cells in which PRC2 is inhibited.
First, we investigated the interaction between PRC2 loss and 
the cytokines that stimulate acute inflammation via TLR and TNF 
signaling in vitro. To this end, we exposed KrasG12D/+;Trp53−/− 
cells to dox-mediated PRC2 inhibition with or without LPS plus 
TNF-α before assessing their colony-formation potential. Nota-
bly, the negative effect of PRC2 loss on colony formation was res-
cued by inflammatory signaling (Fig. S1).
Next, we exploited a ChIP-seq–instructed orthotopic in vivo 
shRNA screening approach (Gargiulo et al., 2013, 2014). This en-
ables screening for potential oncogenes antagonistically regulated 
by PRC2 and inflammation in vivo. For this screen, we selected 
genes that are directly repressed by Ezh2, up-regulated by GSK126, 
and regulated by NF-κB according to IPA. We reasoned that this 
set of 83 genes (hereafter “PRC2-inflammatory mediators”) may 
be enriched for relevant oncogenes driving tumor progression 
upon Ezh2 inhibition by GSK126. With these premises, we per-
formed a parallel in vivo/in vitro screen to systematically interro-
gate the potential regulators of tumor growth. Individual silencing 
in KrasG12D/+;Trp53−/− cells was achieved through a pool of 464 
shRNAs. Statistical representation of this library exceeded 2,000-
fold, which is sufficiently large to compensate for stochastic drop-
out during grafting (Gargiulo et al., 2014). As a functional readout 
to determine significant hits for in vivo dropouts, we included two 
validated anti-Kras shRNAs as controls (Fig. 6 A). To mechanisti-
cally ensure PRC2 depletion at target genes and perform the par-
allel screening procedure under optimal conditions, we chose to 
inhibit PRC2 using a dox-mediated ablation of Eed. Eed depletion 
confers comparable in vivo survival advantage (see below) but is a 
more potent growth inhibitor in vitro compared with GSK126 and 
Ezh2 depletion. In vivo, we used ten animals divided into two pools 
of five, each carrying NSC LC cells transduced at low multiplicity of 
infection with the library and with either one of two independent 
dox-inducible shRNAs (Eedi). In parallel, we compared tumor cell 
growth in vitro under constant dox-mediated Eed depletion alone 
or in combination with LPS plus TNF-α. Importantly, the T0 control 
samples and the in vitro samples showed a substantial similarity in 
PCA and segregated away from the in vivo samples. Moreover, by 
comparing the average hairpin counts for the two groups with the 
different Eed shRNAs, PRC2-inflammatory mediators appeared re-
producibly enriched or depleted (R2 = 0.8; Fig. 6 B; data not shown). 
Overall, the quality of the screen met the criteria for interrogating 
dropout shRNAs as a proxy for pro-oncogenic functions.
Figure 3. Ezh2 inhibition promotes the transcriptional amplification of an inflammatory program at the expense of EGFR/ERBB2 signaling. (A) Outline 
for gene expression profiling of GSK126- or dox-mediated Ezh2 inhibition in KrasG12D/+;Trp53−/−;Ezh2-2A-rTA;Luc lung tumors in vivo upon FACS purification 
followed by RNA-seq. (B) Heat map illustrating up- and down-regulated genes in animals treated with GSK126 for 10 consecutive days (OS50; n = 4) or until 
HuE with GSK126 (n = 3) or dox (n = 1). Fold changes (FC) refer to vehicle-treated animals (n = 2). (C) Heat map illustrating pathway activation inferred by 
PRO GENy scores (color) associated with RNA-seq data for GSK126- and vehicle treated animals. Unsupervised hierarchical clustering was based on Manhattan 
distance. (D) IPA for upstream regulators of genes down-regulated by PRC2 inhibition (counts per million in the vehicle >7, FC < −1.1 in OS50 and HuE). Note 
the concordance with NF-κB/TNF-α activation by PRO GENy. (E) Representative IHC for p-p44/42 in lung tumors with GSK126 or vehicle as validation for EGFR 
signaling down-regulation as in shown in D. (F) As in D, IPA for upstream regulators of genes induced by PRC2 inhibition in all conditions (n = 212, FC > 1.1). (G) 
Selected expression data for potential oncogenes and negative regulators of the antitumor immune response. ****, P ≤ 0.0001. P values were calculated by 
two-way ANO VA and Dunnett post-hoc test. (H) IHC validation of GSK126 up-regulated genes using independent in vivo PRC2 inhibition through dox-mediated 
Ezh2 ablation. GFP knockdown provided control for shRNA activity. (I) Correlation between disease-free survival and overall survival for patients with high or 
normal levels expression levels for the indicated genes in the TCGA NSC LC database. Data are from http:// www .cbioportal .org/ , and the P value was calculated 
using log-rank analysis. (J) Heat map illustrating expression (color) for genes differentially regulated in GSK126- and vehicle-treated animals as well as in tumor 
cells freshly derived from autochthonous lung tumors with the indicated genotypes (DESeq2, P < 0.05). Unsupervised hierarchical clustering for genes was 
based on Pearson correlation. Note the IPA for pathways associated with individual clusters and the concordance with C, D, and F. Scale bars represent 100 µM.
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Figure 4. Transcriptional amplification by Ezh2 inhibition involves PRC2 target chromatin and reinforces NF-κB transcription. (A) Overlap between 
genes up-regulated by GSK126 in vivo (blue) and genes decorated with H3K27me3 at CGI in vivo (red) within the indicated transcriptomes. UpRGs, up-regulated 
genes. (B) UCSC genome browser example of H3K27me3 on the Cxcr4 gene locus in two selected KrasG12D/+;Trp53−/−;Ezh2-2A-rTA;Luc lung tumors in vivo. (C) 
Gene set intensity difference analysis for the indicated gene sets in in vivo PRC2-target chromatin (H3K27me3, n = 4; H3K27ac, n = 2) and control (H2AK5, n = 
2) over control (input, n = 2). Note that initial response to GSK126 (OS50) involves genes decorated by either H3K27me3 or H3K27ac, but not H2AK5ac. RPM, 
reads per million. (D) MA plot for differential gene expression profiling of GSK126 (HuE, n = 3; OS50, n = 4) or vehicle-treated KrasG12D/+;Trp53−/−;Ezh2-2A-
rTA;Luc lung tumors in vivo or in vitro co-cultured with the macrophage cell line Raw264.7. Fold change refers to vehicle-treated controls (n = 2). Quantification 
of up-regulated (blue) and CGI H3K27me3 target genes (red) is limited to the in vivo gene expression (HuE) and chromatin profiles. (E) Immunoblot for the 
indicated antibodies and human NSC LC cell lines upon 5 d of continuous GSK126 treatment and low-confluence replating. MW, molecular weight. (F) Time 
point experiment showing response to TNF-α in GSK126-treated and control A549 cells as gauged by an NF-κB reporter assay. ***, P < 0.001 versus vehicle 
Serresi et al. 
Ezh2 inhibition in Kras-driven NSC LC
Journal of Experimental Medicine
https://doi.org/10.1084/jem.20180801
3123
Interestingly, 113 out of 430 shRNAs scored as dropouts with 
2.8 < X < 10.4–fold changes in lung tumors generated under con-
stant dox-treatment (Fig. 6 C). In vitro, the same approach re-
turned only Kras and L1cam as dropouts (Fig. 6 C). In vivo, our 
selection based on the 2.8 < X < 10.4–fold change window is strin-
gent enough to exclude the least effective Kras hairpin and, as 
such, it critically implicates the remaining PRC2-inflammatory 
mediators in oncogenesis.
To increase the stringency of our analysis further and reduce 
the incidence of off-target effects, we applied a method based 
on linear regression and outlier identification and called as hits 
seven genes that were identified by more than two shRNAs. In-
dependently, we applied two other raw read count–based sta-
tistical methods, EdgeR and DESeq2 (Fig. 6 D). We used in vivo 
genetic complementation as an orthogonal validation of the in 
vivo RNAi screen. We individually overexpressed hits from the 
less conservative method, such as Vav1, Cxcr4, Pltp, Cxcl1, and 
L1cam in Eed-depleted KrasG12D/+;Trp53−/− cells, and used these 
in orthotopic transplantations. Eed depletion conferred signifi-
cant survival extension to the NSC LC-bearing animals (Fig. 6 E), 
which indicates that PRC2 inhibition in vivo using dox-induc-
ible Eedi is comparable to Ezh2i and GSK126 (Fig. 2, D and E). 
Strikingly, when overexpressing individual genes identified as 
“dropout” in our screen, we observed the acquisition of an in-
vasion/metastasis phenotype, a feature that is extremely rare in 
KrasG12D/+;Trp53−/− orthotopic tumors and absent in Eed-depleted 
KrasG12D/+;Trp53−/− controls (Fig. 6, E and F).
Although full comparisons between individual genes are com-
plicated by potential differences in their levels of overexpression, 
this experiment revealed two distinct types of oncogenes. VAV1 
and, to a more limited extent, CXCR4 both imparted prometa-
static activity and also decreased overall survival, but only in 
vivo. Otherwise, L1CAM appeared to be required for growth in 
vitro under inflammatory signaling, while its in vivo overexpres-
sion marked an increase in the prometastatic potential of NSC LC, 
despite the fact that this also appeared to extend the overall sur-
vival (Fig. 6, E and F). Consistent with predictions based on our 
experimental data, correlative analyses showed that NSC LC pro-
gresses faster in TCGA patients with an elevated expression of 
CXCR4, VAV1, and L1CAM (Fig. 6 G).
Collectively, our data indicate that the transcriptional pro-
gram that is amplified in vivo through the inhibition of PRC2 in 
NSC LC includes genes that are (1) downstream proinflammatory 
signaling, (2) pro-oncogenic, and (3) prometastatic.
Ezh2 inhibition enhances responses to BTZ and NM in 
Kras NSC LC grafts
To determine whether the amplification of an inflammatory pro-
gram by GSK126 could be therapeutically exploited in NSC LC, 
we next investigated whether applying GSK126 would enhance 
responses when cells were subsequently treated with a combi-
nation of BTZ plus NM, which target the proteasome-dependent 
activation of NF-κB, and inflammation induced by Kras and Ezh2 
depletion, respectively.
Since KrasG12D/+-driven tumors have been reported to be 
intrinsically resistant to BTZ or quickly develop adaptive re-
sistance (Xue et al., 2011), we first tested whether inhibiting 
PRC2 in vivo would enhance responses to a subsequent treat-
ment using the maximum tolerated dose (MTD) of BTZ/NM. 
Our gene expression profile experiment suggested that 15 d of 
continuous GSK126 exposure is sufficient to stimulate an adap-
tive response involving inflammation. To assess the response to 
each treatment applied individually in vivo, we performed daily 
GSK126 therapeutic interventions in the KrasG12D/+;Trp53−/− 
NSC LC model after verifying tumor take (day 2) and random-
izing the animals into two groups (n = 10 per group). GSK126 
and vehicle mice were further randomized after 15 d to receive 
BTZ, mimicking a previous preclinical validation of BTZ in 
this model (Xue et al., 2011). Under these experimental condi-
tions (Fig. 7 A), we delivered a single MTD of BTZ and NM (see 
Materials and methods). 20 h later, mice were sacrificed and 
randomized for analysis of proliferation/apoptotic markers by 
either immunoblotting or IHC. We observed that GSK126 pre-
conditioning resulted in impaired phospho-Akt and induced 
Parp1 and Caspase-3 cleavage in response to BTZ/NM treatment 
(Fig. 7, B and C).
Next, we decided to test a dosing schedule that could be ap-
plied until the mice reached the HuE. To permit homogenous and 
efficient tumor grafting, mice were treated with GSK126 or ve-
hicle starting from day 4 after transplantation and randomized. 
KrasG12D/+;Trp53−/− tumor-bearing mice with either GSK126 (n 
= 7) or vehicle (n = 6) were longitudinally tested for assessing 
the impact of GSK126 treatment on in vivo tumorigenic poten-
tial of orthotopically transplanted cells by luciferase emission. 
This analysis revealed that at day 18, daily dosages of GSK126 
had significantly impaired tumor proliferation compared with 
vehicle-treated controls, even though the tumors had continued 
to grow compared with their size at day 4, indicating that the 
GSK126 treatment was behaving as expected (Fig.  7, D–G). To 
incorporate a clinically relevant longitudinal imaging of tumor 
responses to GSK126 in vivo, we also tested the animals using 2D 
and 3D magnetic resonance imaging (MRI) and micro–computed 
tomography (micro-CT). The latter detected more clearly good 
responders among the GSK126 cohort (Fig. 7 G).
At day 19, mice were given doses of BTZ and NM in alter-
nation on successive days (Fig. 7 D; Materials and methods). A 
severe shortness of breath signaled the HuE for the vehicle → 
BTZ/NM mice at day 21, while the survival of GSK126 → BTZ/
NM was extended (Fig.  7  F). As above, diseased tissues were 
sorted for either immunoblotting or IHC. Whereas the in-
creased overall survival in the GSK126 cohort may result from 
the additive effect of the sequential drug treatment, GSK126 
significantly promoted the pro-apoptotic response to the BTZ/
NM treatment, as measured by cleaved Caspase-3 in tumors 
by unpaired t test. Genetic tracing reporter is shown (top). UBC, ubiquitin C promoter. NF-κBe, NF-κB responsive element; TAP, minimal TA promoter. (G) Lon-
gitudinal response to TNF-α and LPS in GSK126-treated and control A549 cells. The interaction between time points and treatment is significant by two-way 
ANO VA (P < 0.0001). Data are representative of three independent experiments. Error bars represent mean ± SEM.
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of similar size (Fig.  7, H–J), reinforcing the MTD experiment 
(Fig.  7, A–C). Erk1/2 signaling inhibition was also observed 
using IHC in these mice, consistent with our data with GSK126 
alone (Fig.  7, H and I). Finally, immunoblotting revealed the 
presence of cleaved Parp1 and the inhibition of Erk1/2 and Akt 
phosphorylation in the mice that received full cycles of BTZ/
NM after GSK126 (Fig. 7 J).
We excluded the possibility that additional genetic alter-
ations were contributing to the animals’ response to BTZ/
NM using two independent KrasG12D/+;Trp53−/− cell lines for 
in vivo experiments and sequencing their genomic DNA 
(data not shown).
In summary, our data suggest that the sequential dosing of 
GSK126 and BTZ/NM affect the proliferation and survival of 
NSC LC cells in vivo in a process that potentially involves both 
cell-intrinsic and non–cell-autonomous effects (Fig. 7 K).
Control of RNA synthesis and proteostasis links Ezh2 
inhibition, transcriptional amplification of inflammation, and 
therapeutic vulnerability
We next wished to tackle the complex issue of determining 
the individual responses of lung cancer cells to GSK126 and 
BTM/NM. To this end, our next efforts aimed to disentangle 
the in vivo tumorigenic potential of NSC LC from cellular re-
Figure 5. In vivo Ezh2 inhibition affects the 
tumor microenvironment. (A) Heat map illus-
trating potential immune cells infiltrating the 
orthotopic lung tumors and detected in RNA-seq 
(Fig. 3 B) by cell-type identification by estimating 
relative subsets of RNA transcripts (CIB ERS ORT). 
Quantification of the in vivo–specific populations 
(HuE, n = 3; OS50, n = 4; vehicle-treated controls, 
n = 2) as gauged by two-way ANO VA and Dun-
nett’s post test (bottom). ****, P < 0.0001; **, P 
< 0.01. Rest., resting; act., activated. (B) Models 
depicting potential sources of non–tumor cell–
derived reads in tumor-enriched RNA-seq. (C 
and D) Heat map and box plot illustrating SNP 
quantification from RNA-seq data in Fig.  3  B 
without a reference genome using KisSplice. 
Note the (host-derived) BALB/c reads are signifi-
cantly enriched at an early time point for in vivo 
GSK126 treatment and subsequently depleted 
compared with tumor-derived C57BC/6L reads. 
***, P < 0.001 by one-way ANO VA. (E and F) Bar 
chart quantification of genes bearing BALB/c or 
C57BC/6L SNPs. Shown are all genes (top) and 
those restricted to the IPA category “Cell Move-
ment of Leukocytes” (bottom).
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sponses to Ezh2 inhibition and inflammation. First, we exposed 
KrasG12D/+;Trp53−/− NSC LC cells to GSK126 or BTZ/NM as well as 
sequential GSK126 → BTZ/NM in vitro. We followed this with an 
in vivo assessment of the tumorigenic potential (Fig. 8 A). In-
flammatory signaling stimulation was applied to cells 1 d before 
transplantation and simultaneously with BTZ/NM treatment in 
serum-free medium (IFN; see Materials and methods). After a 
tail vein injection of live cells, all the groups exhibited a similar 
grafting efficiency. Single treatments with either GSK126 or BTZ 
showed impaired tumor progression, as did sequential GSK126 
→ BTZ treatments, as assessed through luciferase emission (two-
way ANO VA; P < 0.0001). Animals treated sequentially with 
GSK126 → BTZ had a significantly higher inhibitory response 
than animals that received single treatments and controls.
Next, we explored the impact of inflammatory signaling on 
cell proliferation and BTZ sensitivity in human cells to determine 
whether it would reveal similar vulnerability to this sequential 
treatment in vitro. KRAS mutant A549 and H1944 lung cancer 
cells were exposed to GSK126 or vehicle in vitro. We reseeded 
them into a 384-well format using either standard RPMI or IFN 
media. The inflammatory medium moderately impaired the 
proliferation of both A549 and H1944 cells under GSK126 treat-
ment and imparted sensitivity to BTZ, regardless of Ezh2 inhi-
bition (Fig. 8 B).
For an unbiased detection of the vulnerabilities of the KRAS 
mutant A549 under inflammatory conditions, we next per-
formed a screen using 293 compounds from two independent li-
braries. These included kinase inhibitors and a National Cancer 
Institute (NCI)–approved oncology drug set. After 5 d, a CellTi-
ter-Blue assay was used to determine cell viability. We screened 
two dosages (30 nM and 300 nM), and after verifying that most 
cytotoxic hits were GSK126 independent under our experimental 
conditions, we focused on the 300 nM dosage, which had a higher 
discovery potential. Remarkably, in both screens, the proteasome 
inhibitors Carfilzomib and BTZ were among the top inhibitory 
compounds (Fig.  8  C), a validation of our hypothesis-driven 
choice for sequential treatments. Surprisingly, five of the top 
ten compounds in the 300 nM screen targeted RNA synthesis, 
with BMS-387032 and flavopiridol (Alvocidib; the NCI-approved 
flavopiridol) specifically targeting CDK(9)-driven transcriptional 
initiation and elongation.
The results of our screen suggested that in the presence of 
inflammatory signaling, A549 cells might selectively rely on RNA 
synthesis. If that were the case, then RNA synthesis would rep-
resent a general mechanism that linked the inhibition of Ezh2 
to the transcriptional amplification of inflammation (Fig. 8 D). 
To test this hypothesis, we treated two independent Kras-driven 
cell lines with GSK126 or vehicle for 5 d and then subjected them 
to low-confluence reseeding, which leads to NF-κB activation in 
the absence of external signaling (Fig. 4 E). To prevent toxicity, 
we limited the incubation period with BMS-387032, flavopiridol 
or vehicle to 4 h. Quantitative RT-PCR (RT-qPCR) showed that 
inhibiting RNA synthesis with both BMS-387032 and flavopiri-
dol abrogated the GSK126-dependent induction of inflammatory 
mediators such as IL-6, Ccl2, and Il1ra in A549 (Fig. 8 D, lower 
left). Similar results were obtained in H1944 cells (Fig. 8 D, lower 
right). Levels of Irak1 were depressed by CDK inhibition even if 
not induced by GSK126, and the maintenance of a steady level of 
transcription of Tgfb1 supported RNA synthesis as a mechanism 
that was required specifically for the induction of inflammatory 
genes (Fig. 8 D).
In summary, our data suggest that Kras-driven NSC LC cells in 
the presence of Ezh2 inhibition and the transcription of inflam-
matory genes selectively rely on proteostasis and RNA synthesis 
to maintain cell fitness.
Discussion
The idea that inhibiting PRC2 might be useful in fighting can-
cer has been around for over a decade (Varambally et al., 2002; 
Bracken et al., 2003; Kleer et al., 2003; Sparmann and van 
Lohuizen, 2006; Margueron and Reinberg, 2011). Correlations 
were found between Ezh2 expression and poor survival in sev-
eral tumors, but specific inhibitors that target PRC2 have only 
shown success in a limited set of genotype-specific tumors that 
exhibit an addiction to polycomb activity (Sneeringer et al., 2010; 
McCabe et al., 2012; Mohammad et al., 2017). On the other hand, 
the recognition that PRC2 proteins have potent tumor-suppres-
Figure 6. In vivo RNAi screening for PRC2-repressed inflammatory mediators with pro-oncogenic potential. (A) Outline of the parallel in vivo/in vitro 
RNAi screen. (B) PCA RNAi screen results. Note the clustering of the in vitro samples and inputs (PC1) as well as the minor variation between individual animals 
(PC2; n = 8, 6, and 10, respectively). (C) Normalized representation of shRNA segregation. The x axis represents individual hairpin relative abundance normal-
ized by total reads count, and the y axis shows fold-change versus input control. The effect of dox-mediated Eed depletion in vitro is compared with input to 
combined dox/LPS/TNF-α treatment and to in vivo proliferation. Each dot represents the mean of two biological and two technical replicas (left, middle, and 
right panels, respectively). The Kras sh#1 dropout control and the newly discovered L1cam sh#1 and sh#2 are shown. In the right panel, in vivo dropout outli-
ers were obtained by one analysis method and are depicted as red diamond signs. Two independent shRNAs targeting Eed were used in vivo (each n = 5). (D) 
Schematic representation of target selection and filtering out of potential off targets. Three analysis methods were used. Asterisks denote genes identified by 
non-linear fit/P < 0.05 EdgeR (*) and/or DESeq2/ P < 0.05 EdgeR (**). FC, fold change. (E) Heat map representation of overall survival and invasion/metastasis 
data. Each animal (column) received 5 × 105 KrasG12D/+;Trp53−/−;Eedi cells (“KPEi”) intravenously and was treated with dox via drinking water (except for “KP” 
controls). Groups are different in the overexpression of individual genes as indicated compared with an empty pLKO.1 vector (n = 4). Invasion and metastasis 
were located using bioluminescence and confirmed through histological analysis. Note that dox-induced Eed loss shows no metastasis (box), while VAV1 gain 
strongly impairs survival and enhances the metastatic phenotype (arrowheads); L1CAM gain enhances the metastatic phenotype while extending survival. 
P values were calculated using the log-rank (Mantel–Cox) test. (F) H&E staining of representative primary tumors and bioluminescence-detected sites of 
distal invasion. KrasG12D/+;Trp53−/−;Eed#a5-2A-rTA;Luc (modified as indicated) were intravenously injected into nude mice, which were sacrificed at the onset of 
shortness of breath and/or metastasis. Scale bars represent 100 µM. N, normal; T, tumor. (G) Correlation between disease-free survival and overall survival 
for patients with high or normal levels expression levels for the indicated genes in the TCGA NSC LC database. PFS, progression-free survival. Data are from 
http:// www .cbioportal .org/ , and P value was calculated using log-rank analysis.
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sive functions urges caution (Koppens and van Lohuizen, 2016); 
targeting PRC2 requires a detailed understanding of adaptive 
responses in vivo, and preclinical tumor models are appropriate 
systems in which this can be pursued. We have recently shown 
that the loss of PRC2 through Eed deletion in Kras-driven adeno-
carcinomas induces sterile inflammation. This leads to the non–
cell-autonomous recruitment of tumor-associated macrophages, 
polarization, and EMT-mediated mucinous differentiation. This 
is an undesirable effect that occurred (depending on the p53 sta-
tus of the tumors) when PRC2 is genetically inhibited in normal 
cells (Gargiulo et al., 2016; Serresi et al., 2016). Here, we show 
that using GSK126 to enzymatically inhibit PRC2 in tumor cells in 
vivo promotes inflammation and microenvironmental changes 
in orthotopic transplantation lung cancer models. Unlike the 
complete PRC2 loss during tumor initiation, pharmacological 
inhibition seems to elicit a cell-cycle restriction also in the most 
aggressive Kras;Trp53 background, and, importantly, it does not 
lead to the development of molecular features such as EMT and 
mucinous differentiation, indicators of tumor progression, that 
have been observed in the autochthonous models. Whether this 
depends on the tumorigenesis phase (progression vs. initiation), 
mode of inhibition (enzymatic interference vs. complete dele-
tion), the duration and the extent of the functional inhibition of 
PRC2, and/or an involvement by components of the tumor micro-
environment is an open question.
In this study, we characterized the response to Ezh2 inhibi-
tion, which entails the amplification of a transcriptional program 
involving NF-κB. In turn, this inflammatory response rewires 
Kras-driven tumors at the molecular level, leading both to the 
activation of a pro-oncogenic and prometastatic program and 
to an increase in vulnerability to treatments that combine BTZ 
and NM. We propose that treating Kras-driven NSC LC by apply-
ing GSK126 in a neoadjuvant-like manner enhances the tumor’s 
susceptibility to subsequent treatments that can be defined ex-
perimentally. Here, we perturbed proteostasis and inflammation 
using small molecules. The combination of BTZ/NM after neo-
adjuvant GSK126 treatment in carcinomas that homogeneously 
express Ezh2 has pro-apoptotic effects alongside modifications 
of the tumor microenvironment (Fig. 7 K). Precisely assessing the 
complex interactions between the drugs in the sequential dosing 
experiments and their impact on the overall survival will benefit 
of additional tumor models such as autochthonous, syngeneic, 
and/or xenografts models.
Phase 3 clinical trials are currently underway using BTZ as a 
therapy to treat NSC LC (i.e., NCT01833143), and second-gener-
ation proteasome inhibitors are being applied in phase 4 trials 
(e.g., NCT03416374). A hypothesis emerging from the current 
study suggests that a combination of proteasome inhibitors with 
other small molecules targeting other associated dependencies, 
such as inflammation and RNA synthesis (e.g., Cox2 and CDK9 
inhibitors, respectively) should be pursued at preclinical level 
and compared with the BTZ and NM combination.
Since the inhibition of Ezh2 has recently been shown to am-
plify TNF-α–induced NF-κB signaling and inflammation in nor-
mal intestinal epithelium (Liu et al., 2017), it is plausible that our 
findings in lung cancer can be extended to other Kras-driven epi-
thelial malignancies, such as pancreatic ductal carcinoma. Future 
studies should be aimed at the systematical characterization of 
the source of upstream signaling of the pathways that we identi-
fied as potentially cooperating with Ezh2 inhibition to drive the 
transcriptional amplification and GSK126-dependent microenvi-
ronmental changes (e.g., TNF-α and JAK/STAT). The difference in 
inflammatory signaling as cell intrinsic or non–cell autonomous 
will potentially determine whether immunotherapy can be a 
major target. Evidence in support of a tight interplay between 
cancer epigenetics and immunology is rapidly accumulating 
(Miao et al., 2018; Pan et al., 2018), and immunotherapy effec-
tiveness as monotherapy is so far restricted to a small set of lung 
cancer patients (Rizvi et al., 2015). In our experimental setting, 
GSK126 induces CD47 and the expression of its cognate receptor 
SIR PA, which has been identified as oncogene in the in vivo RNAi 
screen. Interestingly, CD47 immunomediated depletion proved to 
be effective in preclinical models for NSC LC and evidence indi-
cates a mechanism involving enhanced phagocytosis (Kojima et 
al., 2016; Weiskopf et al., 2016). The identification of a mast cells 
activation signature in a transplantation-based mouse model 
may reflect the outcome of a BALB/c-specific microenvironment. 
Moreover, Ezh2 inhibition also affects macrophages response to 
inflammatory signaling (Zhang et al., 2018). Hence, testing the 
hypothesis involving neoadjuvant-like Ezh2 inhibition followed 
by immunotherapy, such as therapeutic targeting of the CD47/
SIR PA axis, should be extended to relevant autochthonous mod-
els with an intact innate immune system in which PRC2 loss 
causes inflammation (Serresi et al., 2016; Gargiulo, 2018). The 
major outcome of this study is to demonstrate that orthotopic 
grafting of KrasG12D-driven NSC LC promotes homogeneous Ezh2 
expression, whose inhibition in vivo unleashes an inflammatory 
response. During tumor progression, Ezh2 inhibition amplified 
vulnerabilities associated with acute inflammatory transcription 
as revealed by sensitivity of treated tumor cells to inhibition of 
Figure 7. Ezh2 inhibition enhances response to BTZ/NM in Kras-driven NSC LC grafts. (A) Outline of in vivo sequential treatment of KrasG12D/+;Trp53−/− 
grafts with GSK126/vehicle and MTD of BTZ/NM. WB, Western blot. (B and C) Immunoblot and representative IHC (n = 3) of KrasG12D/+;Trp53−/− tumors from A 
using the indicated antibodies. MW, molecular weight. (D) Outline of in vivo sequential treatment of KrasG12D/+;Trp53−/− grafts with GSK126/vehicle and BTZ/
NM. (E) Longitudinal imaging of tumor growth for the experiment in (D) by luminescence. P value is by two-way ANO VA. (F) Overall survival of mice in E. (G) 
Representative micro-CT scans of KrasG12D/+;Trp53−/− vehicle-treated tumors and of good responders to in vivo GSK126 (H, heart; T and arrowheads, tumors). 
(H) Representative IHC (n = 3) of KrasG12D/+;Trp53−/− tumors from D and E using the indicated antibodies. (I) Quantification of cells showing immunoreactivity to 
the indicated antibodies. The full lung area for individual animals (n = 3) was divided into equal-sized fields, and ten fields were subjected to ImageJ automated 
counting. a.u., arbitrary units. (J) Immunoblot of KrasG12D/+;Trp53−/− tumors from D and E using the indicated antibodies. (K) A model for therapeutic PRC2 
inhibition in Kras-driven NSC LC. GSK126 amplifies acute inflammation in Ezh2-expressing NSC LC and modifies the tumor tissue and its microenvironment 
enhancing the response to subsequent selected treatments such as proteasome inhibitors and anti-inflammatory drugs. Error bars represent mean ± SEM. 
Scale bars represent 100 µM. *, P ≤ 0.05; ****, P ≤ 0.0001.
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the cellular machineries involved in proteostasis and RNA syn-
thesis and, indirectly, of the NF-κB pathway. More in general, 
we explored a paradigm of targeting the development of adop-
tive resistance in cases in which preclinical testing supports the 
use of a specific sequential treatment. One example of this ap-
proach has been reported in the case of secondary mutations in 
the MEK–ERK pathway in vemurafenib-resistant BRAF-mutant 
melanomas (Wang et al., 2018). The successful generalization of 
these approaches and systematic clinical application will require 
the identification of predictive biomarkers.
Materials and methods
Mouse strains
All experiments involving animals complied with local and inter-
national regulations and ethical guidelines and were authorized 
by our local experimental animal committee at the Netherlands 
Cancer Institute.
K-rasLSL-G12D/+ (Jackson et al., 2001) and p53F2-10/F2-10 
(Jonkers et al., 2001) mice have been previously described 
(Xie et al., 2014).
Intratracheal and intravenous transplantation
7- to 9-wk-old BALB/c nude mice were intratracheally intu-
bated with 106 cells per 20 μl PBS. For tail vein injections, cells 
were resuspended in 50 μl PBS + 50 μl saline solution. A de-
tailed description of the procedure has been published before 
(Gargiulo et al., 2014).
Cell lines
A549, H1944, H2030, and H2122 human cell lines (provided by the 
R. Bernards laboratory, the Netherlands Cancer Institute, Am-
sterdam, the Netherlands) were cultured in RPMI medium with 
10% FBS and 5% penicillin and streptomycin at 37°C in a 5% CO2–
95% air incubator. Primary mouse NSC LC Kmix and KP cell lines 
were isolated from a KrasG12D/+; and KrasG12D/+;Trp53−/− genetic 
background, respectively. Cells were isolated and propagated 
in F12 medium supplemented with 10% FBS, 5% penicillin and 
streptomycin, hydrocortisone, recombinant EGF, insulin-trans-
ferrin selenium. Raw267.4 cells (ATCC) were cultured in DMEM 
medium with 10% FBS and 5% penicillin and streptomycin at 37°C 
in a 5% CO2–95% air incubator, except when co-cultured with KP 
cells, in which case they were propagated in KP medium.
Expression and knockdown constructs
For Ezh2 knockdown experiments, we used dox-inducible FH1-
tUTG-RNAi vectors (Herold et al., 2008), as described previ-
ously (Michalak et al., 2013), containing the following targeting 
sequences: Ezh2-tetKDa, 5′-GCA AAG CTT GCA TTC ATT TCA3′; 
Ezh2-tetKDb, 5′-GCA ACA CCC AAC ACA TAT AG-3′.
For Eed knockdown experiments, we used dox-inducible 
pLKO.1-Tet-ON containing the following targeting sequences: 
Eed#A5, 5′-GAA GCA ACA GAG TAA CCT TAT-3′; Eed#B4, 5′-CGG CTA 
TTC GAC AAA CCA GTT-3′.
We also performed ablation experiments by using siRNA smart 
pools against mouse EZH2 (ON-TAR GETplus mouse EZH2 siRNA 
L-040882; ON-TAR GETplus non targeting pool D-001810-10-20). 
VAV1, CXCL1, and CXCR4 overexpression constructs were from 
the CCSB-Broad Lentiviral Expression Library in the pLX304-
Blast-V5 vector. pLKO.1-CMV-L1CAM-puro was provided by the 
M. Tsao laboratory (Ontario Cancer Institute, Toronto, Canada) 
and the luciferase vector by the D. Peeper laboratory (Nether-
lands Cancer Institute, Amsterdam, Netherlands).
In vitro and in vivo drug treatment
For in vivo experiments, BALB/c mice (Charles River) were su-
perior to NMRI nude owing to a better response to GSK126. For 
an MTD, BALB/c nude mice received a single treatment via i.p. 
NM (Sigma) and BTZ (LC Labs) in PBS (0.5% DMSO) at 5–1 mg/ 
kg body weight, respectively. To reduce the impact of multiple 
cycles of treatment, BTZ was dosed at 0.8 mg/kg the first day 
and 0.2 mg/kg body weight on the second day, in which 5 mg/kg 
NM was also given.
IVIS Lumina imaging was performed as described previously 
(Gargiulo et al., 2014).
In vitro, NSC LC cells (105 per well) were seeded into 6-well 
tissue culture plates in the appropriate cell culture media 24 h 
before treatment. To induce EZH2 or EED knockdown, cells 
were treated with dox continuously for 5 d. To perform clono-
genic assays, cells treated with dox for 5 d were replated at 250 
Figure 8. Control of proteostasis and RNA synthesis links amplification of proinflammatory genes by GSK126 and therapeutic vulnerability. (A) 
Schematic outline and tumorigenic potential of KrasG12D/+;Trp53−/− mouse NSC LC cells upon in vitro sequential dosing of GSK126, BTZ, and NM. Cells were 
exposed in vitro for 1 wk to 5 µM GSK126 or vehicle followed by 1 d of inflammatory medium (see Materials and methods). Live cells were orthotopically 
transplanted into nude mice (n = 9/10), and luciferase expression was measured at the indicated time points. Note that we used an experimentally derived 
median inhibitory concentration (IC50) for 10 nM BTZ and 50 µM NM because IC50 is >600 µM in mouse and human NSC LC cells. Note the synergism in the 
sequential GSK126/BTZ+NM (all P < 0.0001). P values were calculated by two-way ANO VA. (B) Proliferation of A549 cells ± GSK126 propagated either in RPMI 
+ 10% FBS or serum-free medium with inflammatory cytokines (see Materials and methods). Assessment of dose response to BTZ 96 h after treatment. IC50 is 
shown for each condition. Error bars represent mean ± SEM (n = 4, biological replica), and P value was calculated by one-way ANO VA and Dunnett’s post-hoc 
test. (C) Schematic outline and compound screen in human Kras-driven NSC LC cells. Cells were treated with GSK126 or vehicle as depicted in the schematic 
outline until seeded into 384-well plates. After 24 h, the compound library containing 293 unique pharmacologically active compounds was added into the 
plates. Two concentrations were used (30 nM and 300 nM) in three biological replicates. After 4 d, the medium was changed and supplemented with 1/25th of 
CellTiter-Blue reagent. After 24 h, the cell viability was measured as fluorescence intensity signals with Envision Multilabel Plate Reader. Cumulative frequency 
distribution plot shows drugs affecting A549 survival from left to right. The top ten drugs (inset) and their names and target processes are listed on the right. 
(D) A model explaining how control of RNA synthesis is connected to GSK126 amplification of proinflammatory genes. (E) Schematic outline and RT-qPCR 
assessment response for two independent CDK9 inhibitors from the top ten list in B, flavopiridol (FLA) and BMS-387032 (BMS), in human Kras-driven A549 
and H1944 NSC LC cells. Error bars represent mean ± SEM (n = 3, biological replica), and P value was calculated by two-way ANO VA and Dunnett’s post-hoc 
test. *, P ≤ 0.05; ****, P ≤ 0.0001. CDK, cycline-dependent kinase; CDKi, cycline-dependent kinase inhibitor.
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or 500 cells per well and kept in dox for the duration of the en-
tire experiment. To achieve H3K27 trimethylation inhibition, 
cells were exposed to 0.1% DMSO (vehicle) or 5 µM GSK126 for 
at least 6 d. GSK343 was used at 100 nM concentration for 5 d. 
Western blot analysis was performed using standard methods. 
Whole-cell extracts were prepared in RIPA buffer (50 mM Tris, 
pH 8.0, 50 mM NaCl, 1.0% NP-40, 0.5% sodium deoxycholate, 
and 0.1% SDS) containing protease inhibitor cocktail (Complete; 
Roche) and phosphate inhibitors (10 mM Na fluoride final con-
centration, 1  mM sodium orthovanadate final concentration, 
and 1 mM NaPPi final concentration). Equal amounts of protein, 
as determined by a Micro BCA Protein Assay Kit (Pierce), were 
resolved on NuPage-Novex 4–12% Bis-Tris gels (Invitrogen) and 
transferred onto nitrocellulose membranes (0.2 m; Whatman). 
Membranes were blocked in PBS 0.1% Tween-20 (PBST) 5% BSA 
for 1 h, incubated with primary antibodies in PBST 1% BSA over-
night at 4°C, and incubated with secondary antibodies coupled to 
HRP for 45 min in PBST 1% BSA. Bands were visualized using en-
hanced chemoluminescence Western blotting detection reagent 
(GE Healthcare). Primary antibodies used against the following 
antigens were anti-NFK BSer536 (3033; Cell Signaling), anti–total 
NFKB p65 (C22B4 4764; Cell Signaling), anti-vinculin (clone 
h-VIN1 V9131; Sigma), anti-H3K27me3 (9733; Cell Signaling), an-
ti-EZH2 (612666; BD), anti–phospho-AKT Ser473 (D9E 4060; Cell 
Signaling), total AKT (9272; Cell Signaling), pospho-Stat3 Y705 
(D3A7 9145L; Cell Signaling), anti-PARP (9542; Cell Signaling), 
anti-BMI1 (F6 clone; made in-house), phospho-Erk (9101; Cell 
Signaling), and total Erk (4695; Cell Signaling).
The cell cycle was measured by a BrdU pulse (0.2 mg/ml, 
B9285; Sigma-Aldrich) given 60 min before ethanol fixation. 
FACS analysis was performed after incubation in the dark with 
anti–BrdU-FITC (Becton Dickinson) and propidium iodide (5 μg/
ml; Sigma), in the presence of RNaseA (5 mg/ml).
Luminescence and fluorescence were acquired and quantified 
using a TEC AN SPA RK 20M plate reader with standard settings 
for luminescence, and monochromator excitation/emission, re-
spectively. In all cases, P values were then calculated using Prism.
RT–qPCR and RNA-seq
RNA was isolated using Trizol and cDNA was generated using 
SuperScript II or VILO according to the manufacturer’s instruc-
tions (Invitrogen). Primer details are available upon request. For 
RNA-seq, the library was prepared using TruSeq RNA sample 
prep kit according to the manufacturer’s protocol (Illumina). 
RNA-seq data were deposited in the Gene Expression Omnibus 
(GEO) under accession no. GSE61125.
IHC
For histological analysis, lungs were inflated with formalin and 
fixed for 24 h in formalin. Fixed tissues were subsequently dehy-
drated and embedded in paraffin, and 2- to 10-µm sections were 
prepared and stained with H&E.
We performed IHC for anti-EZH2 (612666; BD), an-
ti-H3K273me (9733; Cell Signaling), anti-GFP (AB6566; AbCam), 
anti–phospho-p44-p42 (rabbit polyclonal 4370; Cell Signal-
ing), anti-CXCR4 (NB100-74396; Novus Biologicals), anti-VAV1 
(NB100-92004; Novus Biologicals), anti-CEPB β (C -19: sc -150; 
Santa Cruz), and anti–cleaved caspase (Asp175, 9661; Cell Sig-
naling). Chromogen system (K3468; DAKO) and Powervision 
Poly-HRP (Leica Microsystems) were used for IHC detection. 
Immunofluorescence used species-specific Alexa Fluor Plus 647 
(Thermo Fisher).
Image quantification
Tumor burden and H3K27me3/DAPI stainings were quantified 
using ImageJ software. The tumor area size was calculated for 
each H&E section by inverting channels until only tumor and no 
normal lung tissue was colored. Automatic quantification was 
performed. A similar approach has been used to calculate colony 
size. For immunofluorescence quantification, all images were 
subjected to the same procedure. Briefly, we imported images in 
ImageJ, converted to 32-bit; the signal was inverted and threshold-
ing used “default” and “AUTO” profiles, and the signal was identi-
fied by “Watershed” function and region of interest parameters 
as follows: size = 0.001 to infinity; circularity = 0.1 to infinity. 
Analyses were performed on the integrated density data (IntDen).
In all cases, P values were then calculated using Prism.
In vivo RNAi screen
The RNAi screen was designed and performed as previously de-
scribed in detail (Gargiulo et al., 2013, 2014). Briefly, a custom-de-
signed library of pLKO.1-encoding shRNAs was assembled from 
the Broad Institute public library. Lentiviral supernatants infec-
tions were performed as described in the references above, and 
NSC LC cells were infected separately by one round of overnight 
exposure to the viral pool. Multiplicity of infection was exper-
imentally designated as <1 due to roughly 50% cell death upon 
1 µg/ml puromycin selection for cells expressing integrated 
shRNA. 0.8–2 × 106 cells were intravenously injected in the tail 
vein, and successful grafting was assessed via noninvasive bio-
luminescence. On the onset of shortness of breathing, animals 
were sacrificed and lung tumors dissected to obtain a single cell 
suspension. BD FAC SAria III (BD Bioscience) was used to sort out 
GFP-positive tumor cells. The genomic DNA was isolated using 
DNeasy tissue and blood kit (Qiagen). 2 μg of DNA was used to 
perform individual shRNA amplification and purification used 
AMPure beads (Ambion). Purified PCR2 products were ready for 
Illumina sequencing and sequenced using HiSeq2000 to iden-
tify the shRNA. Reads were generated in individual tumors and 
counts were log2 transformed, followed by normalization to the 
average of four input samples for individual reads. Data were 
plotted as fold change versus input on the y axis and as normal-
ized abundance (the ratio between individual shRNA counts and 
total read count per tumor sample). Outlier identification was 
performed in Prism using standard xy plots. A strict fold-change 
threshold used was to balance the less conservative parameters 
used in Outlier identification (Gargiulo et al., 2013, 2014).
For both EdgeR and DESeq2 analyses of statistically signifi-
cant hits, we used Seqmonk. Significance by read count quan-
titation using all reads was determined as comparison versus 
input, with a P < 0.05 after Benjamini–Hochberg correction and 
±1(log2) fold change. A custom genome was created with individ-
ual probes named after individual TRC shRNAs. Seqmonk raw 
and normalized counts can be found in Table S1. PCA in Fig. 6 B 
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was performed on all quantitated probes after correcting for total 
count to largest store log transformed.
Drug screen with compound libraries
The screen was performed with the Selleck Kinase Inhibitor Li-
brary as well as the NCI Oncology set. To aim at a final concen-
trations of 30 and 300 nM, we first created DMSO master stock 
plates of 30 and 300 µM, respectively. From these, 100× dilution 
in IFN medium (see below) was obtained first, followed by a 
further 10× to the assay plates (final 1,000×, 0.1% DMSO). The 
concentration of 250 cells per well was experimentally deter-
mined beforehand to take into account proliferation rates over 5 
d and response to cytotoxicity. A549 cells were seeded in 384-well 
Corning black clear-bottom plates using the Multidrop Combi 
(Thermo Scientific) after being resuspended in RHB-A (Takara), 
supplemented with the following cytokines: Heparin-binding 
EGF (HB-EGF; 0.4  µM), NGR1 (3.7  µM), TGF-α (3.8  µM), IL-6 
(1.2 µM), TNF-α (0.9 µM), IFN-γ (0.9 µM), and LPS (4 µM). After 
24 h, the combined NCI-approved oncology drug and Selleck li-
braries set were added using the MIC ROL AB STAR liquid han-
dling workstation (Hamilton). The libraries were stored and 
handled as recommended by the manufacturer. From the mas-
ter plate, 10 mM stocks were diluted to the final concentrations 
in daughter plates containing RHB-A medium. From daughter 
plates, compounds were transferred into 384-well assay plates, 
in triplicate, with final concentrations of 300 nM and 30 nM. 
Compounds were refreshed 48 h later. After 5 d, medium was 
replaced and cells were incubated for 24  h with fresh RHB-A 
supplemented with HB-EGF (0.4 µM), and a CellTiter-Blue assay 
(Promega) was performed as recommended by the manufacturer. 
Fluorescence intensity was measured using the Envision Multi-
label Plate Reader with 544-nm excitation and 590-nm emission 
filters. The cellHTS2 application was used to normalize the data. 
Data were normalized per plate using the normalized percentage 
inhibition method; the mean of the positive control (BTZ) was 
set to 0, and the mean of the negative control was set to 1. Per 
compound and concentration, the mean was determined over the 
three replicates. The screenings were retained for further anal-
yses after verification that the z′factor > 0. Ranking for relative 
viability was based on cumulative frequency distribution and the 
cutoff for Top10 drugs was arbitrary. The full screen results can 
be found in Table S2. Mubritinib (TAK-165) was the most signifi-
cantly GSK126-regulated compound based on a Student’s t test. 
Mubritinib, TAK-733, flavopiridol, and BMS-387032 were all in-
dependently purchased (Selleck) and validated.
Bioinformatic analyses
RNA-seq reads were mapped to the transcriptome using Tophat. 
Gene expression values were determined using HTseq-count. 
In each sample, unique reads were aligned to the reference ge-
nome, and reads mapping to multiple locations were discarded. 
Absolute expression values were normalized to 10 million reads 
followed by log2 transformation. Lowly expressed genes were 
excluded before DRGs were called out. For instance, down-reg-
ulated genes were called out when showing at least a count-per-
million normalized value of >7 and a fold change >1.1. ChIP-seq 
data were obtained from the GEO (accession no. GSE61125). Using 
the seqMIN ER 1.3.2 platform, data were subsequently clustered 
with respect to a list of unique RefSeq genes. Heat maps and the 
average profiles of read density for each cluster were generated. 
We used Kmeans linear as the method of clustering, with the fol-
lowing parameters: left and right extension = 5 kb, internal bins 
(with respect to the gene body) = 120, and number of cluster = 7.
Expression array clustering was performed using the library 
“gplots” in R. “heatmap.2” function has been used to gener-
ate the heat maps and samples has been clusterized by Spear-
man correlation.
The clustering analysis in Fig. 3 J was performed using MeV4.8 
and Pearson correlation. The input DRGs were identified using 
Seqmonk. Briefly, we imported all the .bam files and annotated 
them to the mouse genome (GRCm38). The most stringent filter 
in DESeq2/EdgeR was used at P < 0.02 after Benjamini–Hochberg 
correction. Quantitation was performed using RNA-seq pipeline 
quantitation on merged transcripts counting reads over exons 
correcting for DNA contamination, assuming a non–strand-spe-
cific library. The same procedure in Seqmonk was used to gener-
ate the highlighted gene sets in the MA plot in Fig. 4 C. ChIP-seq 
analysis was performed with Seqmonk, and CpG Island anno-
tation was extended ±5 kb on either side. P values for gene set 
enrichment analysis were generated with the standard gene set 
filter in Seqmonk at P < 0.05 and using correction for multiple 
comparisons. Inputs for the analysis (I58 and I59) were the same 
in all comparisons and were imported from the GEO (accession 
no. GSE61125). The nearest annotated genes to CGIs were used 
to generate the overlap between K27me3+ CGI and DRGs in 
Fig. 4 A using Venny.
In Fig. 4 (A and D), we determined HuE regulated genes using 
EdgeR with a significance below 0.02 after Benjamini–Hochberg 
correction on merged transcripts counting reads over exons as 
raw counts and assuming a non–strand-specific library. This re-
turned 8,554 gene, which were reduced to 6,241 by applying a 
filter for relative expression. Finally, we applied a fold-change of 
>1.5 (log2) over vehicle to identify the final set of 832 up-regu-
lated genes. The overlapping up-regulated genes with H3K27me3 
targets from orthotopic NSCL were 176 out of 2,492 (or 176/832). 
We visualized the same set of genes in all the four plots in Fig. 4 D. 
Using the same criteria in Fig. 4 A, 225 genes were up-regulated 
in OS50 (100/225 were K27me3) and only three in the cells 
treated in presence of LPS + GSK126 KP.
CIB ERS ORT analysis was performed with standard settings, 
and P < 0.001. The number of iterations (either 100 or 1,000) did 
not alter the result of the analysis.
PRO GENy analysis used the pipeline described by the au-
thors (Schubert et al., 2018). Mouse genes were used as input 
after filtering from the original precomputed matrix. KisSplice 
(Lopez-Maestre et al., 2016) allele frequency (Fig.  5, C and D) 
was generated by following the pipeline for nonreference ge-
nome described at http:// kissplice .prabi .fr/ TWAS/ . The refer-
ence genome GRCm38. SNP information for the donor/vehicle 
mice strain was obtained from the Jax database (http:// www 
.informatics .jax .org/ ). BALB.cByJ and C57BL.6J SNP data were 
downloaded from http:// www .informatics .jax .org/ downloads/ .
Correlation, graphical representation and posteriors anal-
ysis were done using R. The frequency distributions in Fig. 5 E 
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were calculated from the allele frequency output of the KisSplice 
procedure. Likewise, the representation in Fig. 5 F was based on 
the same procedure, except that input genes were restricted to 
a significant IPA category based on the IPA core analysis of all 
BALB/c-specific SNPs.
Dose response of NSC LC cells to BTZ under 
inflammatory conditions
A549 and H1944 cells were seeded at low confluency in 384-
well black-walled clear-bottom microplates (Greiner) in either 
RPMI1640 + 10% FBS + 1% Penstrep or IFN medium (RPMI1640 
plus 0.4 µM HB-EGF, 3.7 µM NGR1, 3.8 µM TGF-α, 1.2 µM IL-6, 
0.9 µM TNF-α, 0.9 µM IFN-γ, and 4.0 µM LPS) with and without 
the addition of 5  µM GSK126. After 24  h, BTZ was added in a 
dosage range of 0.01 to 300 nM using the TEC AN d300e com-
pound printer, including four replicates per dosage condition 
with randomized well distribution and DMSO normalization. 
GSK126 treatment was renewed 24 h after the application of BTZ 
using the compound printer. Viability readout was performed 
72 h after drug application using the AlamarBlue assay (Sigma) 
according to the manufacturer’s protocol. Fluorescence intensity 
values were acquired using a TEC AN SPA RK 20M plate reader 
with standard fluorescence top reading settings and monochro-
mator excitation 565 nm (10 nm)/emission 592 nm (10 nm). 
GraphPad PRI SM was used for subsequent data analysis. Con-
centration values in [M] were log transformed, and means of 
fluorescence intensity values of untreated wells were used to 
normalize raw data and plot data points as percentage of via-
bility. A nonlinear regression fit (log(inhibitor) vs. normalized 
response–variable slope) was used to determine IC50 values. P 
values were calculated using one-way ANO VA with post-hoc 
testing of significance.
Database information
The RNA-seq data generated in this study are available at the 
GEO under accession no. GSE61125. The ChIP-seq and RNA-seq 
data generated in a published study were previously deposited 
to the GEO under accession no. GSE61190. Tumor samples with 
mRNA data (RNA Seq V2) for human lung squamous cell carci-
noma (TCGA, provisional, 501 samples) were analyzed at http:// 
www .cbioportal .org.
Online supplemental material
Fig. S1 shows that Eed depletion impairs KrasG12D/+;Trp53−/− cell 
colony formation and that this effect is rescued by TNF-α and 
LPS signaling. Table S1 contains the parallel in vitro/in vivo RNAi 
screen read counts. Table S2 contains normalized compound 
screening data.
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Figure S1. Acute inflammatory signaling rescues Eed depletion. Left: NSC LC cells were cultured as indicated, and colony formation of 250 cells per well 
was assessed. Right: ImageJ quantification. Error bars indicate SD. P value was calculated by ANO VA and Holm–Sidak’s post-test.
Provided online are two Excel files. Table S1 contains parallel in vivo/in vitro RNAi screen data, and Table S2 contains 
compound screen data.
